| AD | Alzheimer’s Disease |
| AQP4 | Aquaporin-4 |
| BBB | Blood–Brain Barrier |
| BCS | Biopharmaceutics Classification System |
| CNS | Central Nervous System |
| COMT | Catechol-O-Methyltransferase |
| CSF | Cerebrospinal Fluid |
| FDA | Food and Drug Administration |
| GI | Gastrointestinal |
| HIF-1α | Hypoxia-Inducible Factor-1 Alpha |
| IL | Interleukin |
| ISF | Interstitial Fluid |
| LDL | Low-Density Lipoprotein |
| LLPS | Liquid–Liquid Phase Separation |
| LPS | Lipopolysaccharide |
| LCTs | Long-Chain Triglycerides |
| MAO-B | Monoamine Oxidase-B |
| MCTs | Medium-Chain Triglycerides |
| MDS-UPDRS | Movement Disorder Society–Unified Parkinson’s Disease Rating Scale |
| NF-κB | Nuclear Factor Kappa-B |
| PD | Parkinson’s Disease |
| PEG | Poly(Ethylene Glycol) |
| PINK1 | PTEN-Induced Kinase 1 |
| PLGA | Poly(Lactic-co-Glycolic Acid) |
| ROS | Reactive Oxygen Species |
| SCFAs | Short-Chain Fatty Acids |
| SNc | Substantia Nigra Pars Compacta |
| SNEDDS | Self-Nanoemulsifying Drug Delivery Systems |
| TLR | Toll-Like Receptor |
| TNF-α | Tumor Necrosis Factor-Alpha |